Hard tissue injuries arising from osteoporosis, trauma, tumor resection, or congenital deformities demand repair strategies that restore both structural integrity and biological function. Traditional approaches rely on autografts or allografts, yet these methods face inherent limitations, including donor site morbidity, insufficient supply, variable graft resorption, and risk of disease transmission. Over the past decade, advances in biomaterials have catalyzed the development of injectable systems that combine minimally invasive delivery with controlled mechanical behavior. These formulations can be introduced percutaneously or through small incisions, conform to irregular defect geometries, and set in situ to provide immediate load-bearing support. Their capacity to integrate with host bone while gradually being replaced by native tissue positions them as transformative tools in orthopedics, craniofacial surgery, and dentistry.

This article examines the fundamental requirements, material classes, reinforcement strategies, and clinical considerations for injectable biomaterials designed for hard tissue repair. Emphasis is placed on achieving mechanical strength comparable to native bone while preserving biocompatibility and bioactivity.

Clinical Need for Minimally Invasive Hard Tissue Repair

The global burden of bone disorders is substantial. Vertebral compression fractures, osteoporotic bone defects, non-union fractures, and craniomaxillofacial defects represent a growing clinical demand. Open surgical procedures, while effective, carry risks of infection, prolonged rehabilitation, and suboptimal cosmetic outcomes. Minimally invasive techniques that rely on injectable materials have gained traction because they reduce surgical trauma, shorten hospital stays, and enable treatment of defects that are difficult to access.

In vertebroplasty and kyphoplasty, for example, injectable polymethyl methacrylate (PMMA) cements have been used for decades to stabilize fractured vertebrae. However, PMMA lacks bioactivity, does not resorb, and can cause thermal necrosis during polymerization. Newer calcium phosphate cements and composite materials aim to overcome these shortcomings by offering degradability, osteoconductivity, and mechanical properties more aligned with cancellous bone.

Essential Properties of Injectable Bone Graft Substitutes

Designing a successful injectable biomaterial requires balancing multiple, often competing, attributes. The following parameters are critical for hard tissue applications:

  • Mechanical strength and modulus matching: The material must withstand compressive forces, shear, and cyclic loading without catastrophic failure. For load-bearing sites, compressive strengths in the range of 10–50 MPa are typically required for cancellous bone, while cortical bone demands values exceeding 100 MPa. Elastic modulus must be tuned to avoid stress shielding and to promote load transfer to adjacent tissue.
  • Injectability and cohesivity: The formulation must flow through a small-gauge needle or cannula without phase separation or filter pressing. Cohesivity prevents the material from disintegrating in contact with fluids during delivery and while setting.
  • Setting time and handling window: A clinically acceptable setting time ranges from 5 to 15 minutes. Too rapid a set compromises injectability; too slow a set risks displacement of the material before it gains strength.
  • Biocompatibility and non-immunogenicity: The material components and their degradation products must not elicit chronic inflammation, cytotoxicity, or allergic responses. Surface chemistry should favor cell adhesion and proliferation.
  • Bioactivity and osteoconductivity: The material should support osteoblast attachment, differentiation, and mineralization. Ideally, it also exhibits osteoinductivity (ability to recruit and differentiate stem cells toward the osteogenic lineage).
  • Controlled degradation: Resorption rate should match the pace of new tissue formation. Premature loss of mechanical support can lead to defect collapse, while excessively slow degradation impedes full remodeling.
  • Radiopacity: Visibility under fluoroscopy or X‑ray is essential for precise placement during minimally invasive procedures.

Material Classes for Injectable Formulations

Calcium Phosphate Cements (CPCs)

CPCs self-harden through a dissolution–precipitation reaction that forms a hydroxyapatite (HA) or brushite phase, closely resembling the mineral component of bone. Their primary advantage is chemical and crystallographic similarity to native bone mineral, which promotes direct bonding and remodeling. Setting can be controlled through the choice of calcium phosphate precursors, liquid‑to‑powder ratio, and addition of setting accelerators or retardants. The compressive strength of CPCs ranges from 20 to 80 MPa, and they can be micro‑ or macroporous depending on processing additives.

Despite these benefits, CPCs are brittle, with fracture toughness typically less than 1 MPa·m1/2, and their injectability can be compromised by filter pressing during extrusion. Recent approaches to reinforcement are discussed in a later section.

Bioactive Glasses and Glass-Ceramics

Bioactive glasses, such as 45S5 Bioglass, release soluble silica, calcium, and phosphate ions upon hydration. These ionic species stimulate osteogenic gene expression and form a hydroxyl carbonate apatite layer that bonds strongly to bone. As injectable materials, bioactive glasses are often incorporated as particles within a carrier paste or combined with CPCs. Their high surface reactivity can accelerate setting and enhance bioactivity. However, their inherent brittleness and difficulty in achieving cohesive injectable pastes remain challenges. Modifications using polymer additives or sol‑gel derived compositions have improved handling and mechanical performance.

Polymer‑Based Composites

Synthetic and natural polymers are used to improve the injectability, toughness, and biological behavior of ceramic‑based systems. Common biodegradable polymers include poly(lactic acid), poly(glycolic acid), and their copolymers (PLGA), as well as natural polymers such as gelatin, chitosan, hyaluronic acid, and alginate. When combined with ceramic fillers (e.g., HA, β‑tricalcium phosphate, bioactive glass), these composites achieve compressive strengths of 5–45 MPa, reduced brittleness, and enhanced cell infiltration due to biodegradation of the polymer phase.

Thermosensitive hydrogels—especially those based on chitosan‑β‑glycerophosphate or poloxamer—can be injected as a sol that gels at body temperature, serving both as a carrier and as a soft tissue‑to‑bone interface material. Their mechanical properties are generally lower than those of CPCs, so they are preferentially used in non‑load‑bearing defects or as composite matrices with ceramic reinforcement.

Magnesium‑Based Metallic Biomaterials

Magnesium and its alloys offer a unique combination of biodegradability, high strength‑to‑weight ratio, and elastic modulus close to that of cortical bone (40–45 GPa). Recent progress in alloy development and protective coatings has mitigated the rapid corrosion and hydrogen gas evolution that historically limited their clinical use. For injectable applications, Mg particles or micropowders are mixed with a carrier phase. As the Mg corrodes, it releases Mg2+ ions that stimulate osteogenesis and angiogenesis, and the corrosion byproducts can be buffered by the surrounding environment in controlled amounts. The mechanical reinforcement provided by Mg particles also improves the compressive and flexural strength of the composite beyond that of the neat matrix.

Reinforcement Strategies to Enhance Mechanical Strength

Native bone is an elegant composite of collagen and mineral nanoparticles that achieves both stiffness and toughness. Injectable biomaterials must replicate this performance within the constraints of a flowable precursor. The following reinforcement approaches have shown promise.

Nanoscale Reinforcements

Incorporation of nanofibers, nanowires, or nanoparticles can dramatically improve mechanical properties with minimal effect on injectability. Nano‑hydroxyapatite (nHA), graphene oxide (GO), carbon nanotubes (CNTs), and cellulose nanocrystals have all been investigated. For instance, GO sheets functionalized with poly(ethylene glycol) dispersed in CPCs can increase compressive strength by 40–60% and improve fracture toughness through crack bridging and deflection. Similarly, CNTs loaded at low weight fractions (0.5–2 wt%) significantly enhance flexural modulus and reduce brittleness without cytotoxic effects when surface‑functionalized. Care must be taken to ensure uniform dispersion and to avoid aggregation, which can clog needles or create mechanical weak points.

Fiber Reinforcement for Toughness

Discontinuous short fibers (carbon fibers, polymeric fibers such as polycaprolactone, or resorbable Vitrigel fibers) can be incorporated into injectable pastes. As the material cures, fibers bridge cracks and increase the work of fracture. Studies on CPCs containing 5–15 wt% polypropylene fibers have shown a twofold increase in flexural strength and a tenfold increase in impact resistance. The fiber length (0.1–3 mm) must be optimized to avoid interfering with flow through a nozzle or cannula.

Dual‑Setting and Interpenetrating Networks

A particularly effective concept is the combination of two independent polymerization pathways. For example, a CPC formulation can include a biodegradable hydrogel that undergoes covalent crosslinking immediately after injection. The hydrogel network confers cohesive strength and prevents washout, while the ceramic phase provides compressive resistance. These dual‑setting systems can reach compressive strengths exceeding 90 MPa and show improved fatigue behavior. Interpenetrating polymer networks of chitosan and gelatin crosslinked with genipin or transglutaminase, combined with ceramic particles, represent another evolving platform.

Delivery Apparatus and Clinical Workflow

The clinical deployment of injectable biomaterials requires careful attention to mixing, delivery, and setting control. Prefilled dual‑chamber syringes are common, where powder and liquid are mixed immediately before injection. Static or dynamic mixers ensure homogeneity. The viscosity of the paste must be low enough for injection through a 10‑ to 14‑gauge needle yet high enough to prevent leakage into the surrounding tissue.

Setting time is often tailored by additives such as citric acid (for accelerator action) or chitosan (for retardation). The addition of computed tomography (CT) or fluoroscopic guidance allows precise placement. For vertebral augmentation, a cannula is inserted through the pedicle, and the material is injected under real‑time imaging to monitor filling and detect extravasation.

Recent work has also explored the use of robotic injection systems and image‑based feedback to optimize flow rate and pressure, reducing the risk of cement leakage.

Bioactivity and Osseointegration Mechanisms

Beyond mechanical performance, an injectable biomaterial must promote bone healing. This involves a sequence of events: adsorption of proteins from blood and tissue fluids, adhesion and migration of osteogenic cells, deposition of mineralized matrix, and eventual replacement by lamellar bone. The ideal injectable material should present a micro‑ and nano‑topography that mimics the extracellular matrix, release osteoinductive signals, and degrade at a pace that allows progressive vascularization and remodeling.

Incorporation of growth factors—such as bone morphogenetic protein‑2 (BMP‑2), vascular endothelial growth factor (VEGF), or fibroblast growth factor (FGF)—into injectable formulations has demonstrated accelerated healing in preclinical models. However, dose optimization and controlled release remain critical to avoid ectopic bone formation or over‑stimulation. Carrier systems like PLGA microspheres, liposomes, or mesoporous bioactive glass nanoparticles are used to embed growth factors within the injectable matrix.

Some materials, such as bioactive glasses and silicon‑substituted calcium phosphates, stimulate osteogenesis through direct ionic signaling rather than exogenous growth factors. This “intrinsic bioactivity” can simplify regulatory pathways while still achieving robust bone regeneration.

Current Limitations and Unmet Clinical Needs

Despite considerable progress, several hurdles persist before injectable biomaterials can fully supplant autografts for all indications.

  • Fatigue resistance and long‑term stability: Most injectable cements are brittle and prone to fatigue fracture under cyclic loading. In weight‑bearing sites like the femoral head or tibial plateau, catastrophic failure can occur before sufficient bone ingrowth has occurred.
  • Degradation‑strength trade‑off: Materials that degrade rapidly lose mechanical support prematurely. Balancing these aspects requires sophisticated composite architectures and adaptive degradation kinetics.
  • Infection risk: Any foreign material can become a nidus for bacterial colonization. Antibiotic‑eluting injectable biomaterials have been developed (e.g., gentamicin‑loaded CPCs), but sustained efficacy against resistant organisms is still under investigation.
  • Rheological predictability: Small variations in ambient temperature, mixing technique, or powder moisture content can alter viscosity and setting time, leading to inconsistent clinical outcomes.
  • Regulatory pathway: Demonstrating equivalence to existing predicate devices or proving safety and efficacy through clinical trials can be lengthy and costly, particularly for novel combination products that incorporate biologics or cells.

Emerging Frontiers in Injectable Biomaterials

3D‑Printed Injectable Scaffolds

Advancements in 3D printing now allow the fabrication of patient‑specific porous implants that can be injected in a compact form and then expanded or shape‑fixed in situ. Shape‑memory polymers, nitinol‑based materials, and modified CPCs can be printed into a compressed architecture that expands upon hydration or temperature change. This approach combines the advantages of preoperative planning and customization with the minimal invasiveness of injection.

Gene‑Activated Matrices

Injecting non‑viral vectors carrying osteogenic genes (e.g., BMP‑2 or Runx2) embedded within a biodegradable carrier enables local transfection of cells that migrate into the defect site. Gene‑activated injectable matrices have shown promise in bridging critical‑size defects in animal models, reducing the need for high‑dose recombinant protein delivery.

Artificial Intelligence and Machine Learning

Machine learning models are being used to predict optimal compositional ratios for injectability and ultimate strength. By training on datasets of formulation parameters, these algorithms can identify non‑intuitive combinations that achieve target properties, accelerating material discovery. In the future, such models could be integrated into the clinic to tailor materials in real time based on patient‑specific imaging data.

Smart and Stimulus‑Responsive Systems

Materials that respond to pH, enzymatic activity, or mechanical load are on the horizon. For instance, injectable hydrogels that stiffen when exposed to the alkaline microenvironment of active bone remodeling could provide adaptive support exactly where and when it is needed. Similarly, self‑healing injectable biomaterials can recover microcracks autonomously, extending the service life of the implant while bone regeneration proceeds.

Conclusion

The development of injectable biomaterials for hard tissue repair has evolved from simple polymer or cement plugs to sophisticated, mechanically robust composites that actively participate in the healing process. By combining calcium phosphate chemistry with polymer or metallic reinforcement, nanoscale additives, and controlled delivery of bioactive cues, these materials can now provide immediate mechanical stability while supporting full osseous regeneration. Challenges related to fatigue resistance, degradation control, and clinical repeatability remain, but ongoing advances in dual‑setting formulations, 3D printing, and artificial intelligence promise to close these gaps. As the field continues to mature, injectable biomaterials are poised to become the standard of care for an expanding range of orthopedic, dental, and craniofacial applications, delivering both structural restoration and biological repair with minimal surgical impact.

Further reading: Acta Biomaterialia: Injectable biomaterials for bone repair & FDA biomaterials overview & Clinical outcomes of injectable calcium phosphate cement